These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32219445)

  • 1. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice.
    Shide K; Kameda T; Kamiunten A; Ozono Y; Tahira Y; Yokomizo-Nakano T; Kubota S; Ono M; Ikeda K; Sekine M; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Iwakiri H; Hasuike S; Nagata K; Sashida G; Shimoda K
    Blood; 2020 Jul; 136(1):106-118. PubMed ID: 32219445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
    Shide K; Kameda T; Yamaji T; Sekine M; Inada N; Kamiunten A; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Shimoda H; Kitanaka A; Honda A; Sawaguchi A; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Hasuike S; Yamamoto S; Nagata K; Shimoda K
    Leukemia; 2017 May; 31(5):1136-1144. PubMed ID: 27807369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Detection of CALR-Mutated Cells in Myeloproliferative Neoplasm-Related Glomerulopathy With Interstitial Extramedullary Hematopoiesis: A Case Report.
    Maruyama K; Nakagawa N; Suzuki A; Kabara M; Matsuki M; Shindo M; Iwasaki S; Ogawa Y; Hasebe N
    Am J Kidney Dis; 2019 Dec; 74(6):844-848. PubMed ID: 31377025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
    Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
    Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish.
    Lim KH; Chang YC; Chiang YH; Lin HC; Chang CY; Lin CS; Huang L; Wang WT; Gon-Shen Chen C; Chou WC; Kuo YY
    Blood Cancer J; 2016 Oct; 6(10):e481. PubMed ID: 27716741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
    Han L; Schubert C; Köhler J; Schemionek M; Isfort S; Brümmendorf TH; Koschmieder S; Chatain N
    J Hematol Oncol; 2016 May; 9(1):45. PubMed ID: 27177927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic expression of a chimeric murine-human CALR oncoprotein allows the assessment of anti-CALR antibody immunotherapies in vivo.
    Achyutuni S; Nivarthi H; Majoros A; Hug E; Schueller C; Jia R; Varga C; Schuster M; Senekowitsch M; Tsiantoulas D; Kavirayani A; Binder CJ; Bock C; Zagrijtschuk O; Kralovics R
    Am J Hematol; 2021 Jun; 96(6):698-707. PubMed ID: 33761144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloproliferative neoplasm stem cells.
    Mead AJ; Mullally A
    Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
    Edahiro Y; Araki M; Komatsu N
    Cancer Sci; 2020 Aug; 111(8):2682-2688. PubMed ID: 32462673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
    Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
    Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Mutated Calreticulin in the Pathogenesis of
    Vadeikienė R; Jakštys B; Laukaitienė D; Šatkauskas S; Juozaitytė E; Ugenskienė R
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.
    Wang J; Hao J; He N; Ji C; Ma D
    Turk J Haematol; 2016 Sep; 33(3):180-6. PubMed ID: 26377485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
    Dunbar A; Nazir A; Levine R
    Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
    Martin S; Wright CM; Scott LM
    Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
    Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
    Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis.
    Rivera JF; Baral AJ; Nadat F; Boyd G; Smyth R; Patel H; Burman EL; Alameer G; Boxall SA; Jackson BR; Baxter EJ; Laslo P; Green AR; Kent DG; Mullally A; Chen E
    Blood Adv; 2021 Apr; 5(7):1922-1932. PubMed ID: 33821991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.
    Wiriyaukaradecha K; Nimsanor S; Tantirukdham N; Tongsom J; Bunyoo C; Soonklang K; Sritana N; Auewarakul C
    Asian Pac J Cancer Prev; 2022 May; 23(5):1671-1678. PubMed ID: 35633552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of calreticulin mutations in myeloproliferative neoplasms.
    Araki M; Komatsu N
    Int J Hematol; 2020 Feb; 111(2):200-205. PubMed ID: 31848992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations.
    Takei H; Edahiro Y; Mano S; Masubuchi N; Mizukami Y; Imai M; Morishita S; Misawa K; Ochiai T; Tsuneda S; Endo H; Nakamura S; Eto K; Ohsaka A; Araki M; Komatsu N
    Br J Haematol; 2018 Jun; 181(6):791-802. PubMed ID: 29741776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.